TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Alvimopan as Rescue in Post op Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have benign or malignant colonic or rectal disease that have undergone laparoscopic or open colorectal resection, small bowel resection or ileostomy reversal with small bowel resection and subsequently developed postoperative ileus, defined as:~   * Return to NPO status after initial diet attempts, or~  * Placement of nasogastric tube~2. Subjects who are 18 years of age and older~3. Subjects of either gender~4. Subjects who are willing and able to adhere to protocol requirements, agree to participate in the study program and provide written and informed consent.~Exclusion Criteria:~1. Subjects who received Entereg preoperatively.~2. Subjects that have taken therapeutic doses of opioids for more than 7 days immediately prior to surgery.~3. Subjects with severe hepatic impairment.~4. Subjects with end-stage renal disease.~5. Subjects who are pregnant.~6. Subjects who were diagnosed with a complete small bowel obstruction preoperatively.~7. Subjects with a medical condition that may interfere with the use of the study medication Entereg.~8. Subjects who have a condition or general disability or infirmity that in the opinion of the investigator precludes further participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvimopan group (Type: EXPERIMENTAL): In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
- Control Group (Type: OTHER): Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nodal Staging in Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy~* Histologically or cytologically confirmed endometrioid-type endometrial cancer confined to the uterine corpus~* No clinical evidence of extra-uterine disease on pre-operative evaluation.~* Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.~* Age ≥18 years.~* Life expectancy (estimated survival) of at least 6 months.~* AST(SGOT)/ALT(SGPT) \< 3.0X upper limit of normal~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* GOG/ECOG Performance Status greater than 2~* Non-endometrioid cell type~* Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam~* Previous vaginal, pelvic or abdominal irradiation~* Chemotherapy, hormone therapy or immunotherapy directed at the present disease~* Previous pelvic lymphadenectomy or retroperitoneal surgery~* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen~* Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition~* Patients with uncontrolled intercurrent illness~* Patients with psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sentinel Node Surgical Staging (Type: EXPERIMENTAL): None
- Selective Surgical Staging (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MESA Rail™ AIS Study - Preservation of Curve Correction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AIS requiring surgical treatment for selective thoracic/lumbar fusion with a minimum of five (5) instrumented vertebrae between T1-S1 as confirmed by patient history and radiographic studies. AIS cases must be classified as a Lenke type 1 or type 2 curve. No cervical vertebrae are to be incorporated into the construct.~* Willingness and ability to comply with the requirements of the protocol including follow-up requirements.~* Willing and able to sign a study specific informed consent form or, in the case of a patient who is a minor, provide assent and the minor patient's parent/legal guardian provides written consent to participate.~* Age range of ≥ 11 years old and ≤ 21 years old at time of surgery.~Exclusion Criteria:~* Previous anterior or posterior spine surgery at the index levels.~* Previous posterior spine surgery (e.g., posterior element decompression) that destabilizes the cervical/thoracic/lumbar spine.~* Active systemic infection or infection at the operative site.~* Co-morbid medical conditions of the spine or upper/lower extremities that may affect the thoracic or lumbar spine neurological and/or pain assessment.~* Metabolic bone disease such as osteoporosis that contradicts spinal surgery.~* History of an osteoporotic fracture.~* History of an endocrine or metabolic disorder (e.g., Paget's disease) known to affect bone and mineral metabolism.~* Taking medications that may interfere with bony/soft tissue healing including chronic steroid use.~* Known allergy to titanium or cobalt chrome.~* Rheumatoid arthritis or other autoimmune disease or a systemic disorder such as HIV, active hepatitis B or C or fibromyalgia.~* Insulin-dependent type 1 or type 2 diabetes.~* Medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion.~* Pregnant, or intend to become pregnant, during the course of the study.~* Severe obesity (Body Mass Index \> 40).

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- AIS (Type: None): Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing uni- or bilateral delayed abdominally-based breast reconstruction at the Cleveland Clinic.~* Women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study.~* Capable of providing written informed consent prior to any protocol-specified procedures.~* Willing to adhere to the study visit schedule and other protocol requirements.~Exclusion Criteria:~* BMI \> 37~* Women who are pregnant, nursing, or planning pregnancy during the trial.~* Have a serious concomitant illness that could interfere with the subject's participation in the trial (allergy preventing supplement usage)~* Undergoing chemotherapy during proposed nutritional intervention (3 months before or after surgery).~* Are unable to or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.~* Clinical diagnosis of cognitive impairment or dementia.~* Known sensitivity to nutritional supplements.~* History of being seen or had intervention/care in Functional Medicine or following Functional Medicine principles.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Standard of Care (SOC)) (Type: ACTIVE_COMPARATOR): Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
- SOC + Functional Medicine (Type: EXPERIMENTAL): Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.~Perioperative nutrition and lifestyle-based interventions along with select dietary supplements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone's Effect on the Cardiovascular System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult between the ages of 18 and 65~* Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml~Exclusion Criteria:~* Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits.~* Personal history of diabetes mellitus or development of diabetes between study visits.~* Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit.~* Initiation of regular tobacco use between baseline and follow-up study visit.~* Pregnancy or nursing~* Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is a healthy adult 18 to 75 years of age, inclusive, in general good health and with diagnosis of knee OA, as determined by the American College of Rheumatology (ACR) clinical/radiographic classification criteria for OA of the knee.~* Women must be of non childbearing potential (amenorrhea for at least 1 year PLUS have a serum follicle stimulating hormone (FSH) level \>30 IU/L, bilateral oophorectomy or hysterectomy), and have a confirmed negative serum pregnancy test at the screening visit prior to randomization.~Exclusion Criteria:~* History of other diseases that may involve the study joint, including inflammatory joint diseases, crystalline disease, endocrinopathies, metabolic diseases, infections, neuropathic disorders, avascular necrosis, Paget's disease, or tumors.~* Women of childbearing potential, or who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison on the Efficacy of a Monophasic

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical outcomes of patients who suffered a cardiac arrest while hospitalized and were resuscitated after biphasic defibrillators were implemented in 2001 to clinical outcomes of patients who suffered cardiac arrest before 2001.~Exclusion Criteria:~Biphasic defibrillators were implemented Cardiac arrest before 2001

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Case:~Patients resuscitated after 2001
- 2 (Type: None): Control:~Patients who suffer cardiac arrests after 2001.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Testing if Reductions in Negative Affect Yield Decreased Emotional Eating Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female between the ages of 18 and 45 years of age~* An emotional eating score more than one SD above the mean (\>2.9) on the Dutch Eating Behavior Questionnaire (DEBQ) emotional eating scale (van Strien, Frijters, Bergers, \& Defares, 1986).~* Regular computer and internet access~* Rate liking of vanilla frozen yogurt as a 6 or higher on a 10 point scale.~Exclusion Criteria:~* Body mass index (BMI; kg/m2) less than 18.5 (World Health Organization, 2000), given known cognitive impairments that can result from being underweight (Fowler et al., 2006).~* Current psychotic, manic, or substance use disorders, as these may interfere with their ability to cognitively engage in the intervention.~* Food allergies that would prevent consumption of vanilla frozen yogurt.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive Bias Treatment (Type: EXPERIMENTAL): Intervention condition
- Relaxation Condition (Type: ACTIVE_COMPARATOR): Active control condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Superficial TCC: Any G3 or any T1 and/or CIS~* Multifocal (\>1) Ta lesions~* Multiple recurrences (\>2) of Ta lesions in the last 24 months~* Complete tumor eradication must be confirmed~* WHO performance status 0-2 (Appendix V)~* Life expectancy of more than 24 months~* Patients willing to sign informed consent~Exclusion Criteria:~* Bladder tumors other than TCC~* Coexistence of another primary malignant tumor other than BCC of the skin~* TCC of the bladder involving the urethra or upper urinary tract~* Previous history of TCC stage T2 or higher~* Clinical presence or previous history of regional spreading or distant metastases~* Intravesical MMC treatments during the last 12 months~* Previous intravesical BCG therapy (Any intravesical BCG therapy in the last 24 months, or More than 6 BCG intravesical instillations in the last 48 months.~* Previous pelvic radiotherapy or systemic chemotherapy~* Partial cystectomy~* Diverticle of bladder larger than 1cm in diameter~* Residual urine \> 100cc measured by uroflowmetry~* Bladder volume \< 150cc measured by ultrasound~* Urinary incontinence (more than one wet pad a day)~* Urethral stricture impeding 20F catheterization~* Urethral bleeding or persistent hematuria~* Active intractable or uncontrollable UTI~* Active tuberculosis or BCG infection~* Patients who experienced BCG life threatening sepsis~* Known allergy to MMC or BCG~* Known impaired immune response, positive HIV serology, patients receiving systemic steroids or immunosuppressive therapy~* Hematological disorders; leukocytes \< 3500, platelets \< 100,000~* Kidney or liver function disorders (more than 1.5 times upper normal limit)~* Pregnant or lactating women~* Patients who cannot be followed up properly or are unable to collaborate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Synergo + MMC (Type: EXPERIMENTAL): Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
- Bacillus Calmette-Guérin (Type: ACTIVE_COMPARATOR): Intravesical instillation with BCG (Bacillus Calmette-Guérin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Synchronized vs. Continuous HFNC Using NAVA on WOB in Infants With BPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological age greater than 28 days~* Gestational age at birth less than 32 weeks and 6 days~* Diagnosis of BPD (supplemental oxygen requirement for greater than or equal to 28 days)~* Currently receiving noninvasive ventilation support (NIV NAVA, NIPPV, nCPAP, HFNC)~Exclusion Criteria:~* Major congenital anomalies of the heart and lungs~* Post menstrual age greater than 50 weeks 0 days~* Oxygen requirement greater than 40%

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with synchronized) (Type: EXPERIMENTAL): Subjects will first receive HFNC synchronized to his/her own efforts via NAVA at 6 LPM followed by continuous HFNC at 6 LPM and then HFNC synchronized to his/her own efforts via NAVA at 8 LPM followed by continuous HFNC at 8 LPM
- Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with continuous) (Type: ACTIVE_COMPARATOR): Subjects will first receive continuous HFNC at 6 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 6 LPM. Next, subjects will receive continuous HFNC at 8 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 8 LPM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Traditional vs. Graft-augmented Posterior Colporrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Posterior wall defect with point Ap or Bp at 0 or greater~* Desires surgical correction~* Willing to accept randomization to graft vs. no graft~* Competent to sign an informed consent~* Completed childbearing~* Non-pregnant~Exclusion Criteria:~* Current anal sphincter disruption with planned incontinent surgical repairs~* Poor surgical candidate~* History of rectal cancer or inflammatory bowel disease~* Current rectovaginal~* History of vaginal cancer~* History of vaginal/pelvic radiation~* Foreshortened vagina~* Previous adverse reaction to Xenform matrix graft material

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Posterior repair with graft augmentation.
- 2 (Type: OTHER): Posterior repair without graft augmentation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Between 18-35 years of age~* 37 weeks gestation~* Breech presentation~Exclusion Criteria:~* Patients with ruptured membranes~* Multiple gestation~* Maternal age (age \> 35)~* With known medical comorbidities (including hypertension (HTN), arrhythmias, endocrinologic diseases such as diabetes and thyroid disease, scoliosis, asthma)~* Allergies to nitroglycerine or terbutaline~* Prior abdominal or uterine surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous Terbutaline (Type: ACTIVE_COMPARATOR): 0.25 mL of Intravenous Terbutaline
- Intravenous Nitroglycerine (Type: ACTIVE_COMPARATOR): IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues